TLDR
- Geron (GERN) drops 5% to $1.78 after TD Cowen cuts price target ahead of earnings release.
- TD Cowen lowers GERN target from $4 to $3 while maintaining Buy rating before Q4 results.
- GERN breaks below $1.88 range and tests $1.75 support amid sustained selling pressure.
- Geron guides 2026 RYTELO revenue at $220M–$240M with lower operating expenses projected.
- Company advances Phase 3 IMpactMF trial while expanding RYTELO commercialization efforts.
Geron Corporation (GERN) fell 5.33% to $1.78 after sustained intraday selling pressure. The stock broke below the $1.88 to $1.90 range and printed lower highs by midday. The decline followed a price target cut by TD Cowen ahead of the company’s fourth quarter earnings report.
Geron Slides After TD Cowen Lowers Price Target
Geron shares moved lower after TD Cowen reduced its price target to $3 from $4. The firm maintained its Buy rating while adjusting expectations before earnings. The company plans to report fourth quarter results on February 25.
The stock traded down to $1.78 and marked a sharp intraday breakdown. Sellers pushed the price below the $1.88 to $1.90 area during early trading. Momentum remained negative as the stock formed lower highs into midday.
Support now stands between $1.77 and $1.75 based on recent price action. A move below that range could extend the short term downtrend. The stock would need to reclaim $1.85 to show near term stabilization.
Geron (GERN) Outlines 2026 Revenue and Expense Targets
Earlier in January, Geron released its financial guidance for 2026. The company expects RYTELO’s net product revenue to be etween $220 million and $240 million. It projects total operating expenses between $230 million and $240 million.
The guidance reflects anticipated revenue growth and a year-over-year reduction in operating expenses. Management stated that the outlook supports the company’s balance sheet strength. The company continues to focus on disciplined cost management alongside commercial expansion.
Geron identified key priorities for 2026 within its strategic plan. The company aims to grow RYTELO commercially across the United States. It also plans to explore expansion into lower-risk myelodysplastic syndromes markets outside the United States.
Geron Advances Commercial and Clinical Programs
Geron operates as a commercial-stage biopharmaceutical company focused on blood cancers. Its lead product, RYTELO, targets patients with specific hematologic conditions. The company continues to build its commercial presence following the product launch.
Geron advances its Phase 3 IMpactMF clinical trial. The study evaluates treatment options for patients with myelofibrosis. Clinical development remains central to the company’s long-term growth strategy.
The recent share decline comes as the company approaches its earnings release. Market activity reflected an immediate reaction to the revised price target. Geron now trades near short-term support levels while preparing to report quarterly results.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
